Patents Assigned to SUMITOMO PHARMA AMERICA, INC.
  • Salts, crystal forms, and production methods thereof
    Patent number: 11987591
    Abstract: Provided are salts of (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine and various of crystal forms thereof, and compositions, medicaments, pharmaceutically acceptable formulations thereof, and methods of making same. In addition, provided are compounds comprising specific particle size distributions of crystalline (S)-(4,5-dihydro-7H-thieno[2,3-c]pyran-7-yl)-N-methylmethanamine HCl and methods of making and modulating the particle size distributions.
    Type: Grant
    Filed: July 22, 2022
    Date of Patent: May 21, 2024
    Assignee: Sumitomo Pharma America, Inc.
    Inventors: Andrea Bauer, Nandkumar Nivritti Bhogle, Xiaoxia Chen, Shahla Jamzad, Robert Joseph Prytko, Kostas Saranteas, Michael Joseph Sizensky, Harold Scott Wilkinson, Haitao Zhang
  • FUSED DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS
    Publication number: 20240158416
    Abstract: Disclosed are fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analog compounds, and pharmaceutically acceptable salts thereof; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
    Type: Application
    Filed: April 6, 2022
    Publication date: May 16, 2024
    Applicant: Sumitomo Pharma America, Inc.
    Inventors: Milan CHYTIL, Michele HEFFERNAN, Linghong XIE
  • Compounds and compositions and uses thereof
    Patent number: 11958862
    Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: April 16, 2024
    Assignees: Sumitomo Pharma America, Inc., PGI Drug Discovery LLC
    Inventors: Linghong Xie, Michele L. R. Heffernan, Philip Glyn Jones, Taleen G. Hanania
  • JAK2 AND ALK2 INHIBITORS AND METHODS FOR THEIR USE
    Publication number: 20240083855
    Abstract: Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: October 23, 2023
    Publication date: March 14, 2024
    Applicant: SUMITOMO PHARMA AMERICA, INC.
    Inventors: Alexis MOLLARD, Steven L. WARNER, Gary A. FLYNN, Hariprasad VANKAYALAPATI, David J. BEARSS